Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
| CRNX Stock | USD 53.60 0.86 1.63% |
Slightly above 54% of Crinetics Pharmaceuticals' investor base is interested to short. The analysis of the overall investor sentiment regarding Crinetics Pharmaceuticals suggests that many traders are impartial. Crinetics Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Crinetics Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Crinetics |
FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025SAN DIEGO, Dec. 09, 2024 -- Crinetics Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration accepted its New Drug Application for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the first and only once-daily, oral, selective somatostatin receptor ty
Read at finance.yahoo.com
 |
Crinetics Pharmaceuticals Current Investor Sentiment
Panic Vs Confidence
46
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Crinetics Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Crinetics Pharmaceuticals.
News SentimentBullish | Hype SentimentBullish | Insider SentimentDisposing |
Crinetics Pharmaceuticals Fundamental Analysis
We analyze Crinetics Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crinetics Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crinetics Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Crinetics Pharmaceuticals is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Crinetics Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Crinetics Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Crinetics Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Crinetics Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Crinetics Pharmaceuticals Related Equities
| INBX | Inhibrx | 5.19 | ||||
| CYTK | Cytokinetics | 4.56 | ||||
| ALEC | Alector | 4.49 | ||||
| RGNX | Regenxbio | 2.83 | ||||
| PASG | Passage Bio | 1.54 | ||||
| BDTX | Black Diamond | 1.37 | ||||
| MRUS | Merus BV | 0.57 | ||||
| VRDN | Viridian Therapeutics | 1.06 | ||||
| KRON | Kronos Bio | 2.11 | ||||
| KZR | Kezar Life | 2.15 | ||||
| LYEL | Lyell Immunopharma | 4.69 | ||||
| GPCR | Structure Therapeutics | 6.91 |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.